Find out what Remsima Could do for you - The world’s fist biosimilar monoclonal antibody (mab) approved by EMA, FDA, and other competent regulatory authorities around the world for the treatment of autoimmune diseases.

Remsima® ▼ is subject to additional monitoring

If you experience any side effects when taking Remsima® ▼ or any other medicine, talk to your doctor, pharmacist or nurse. This includes possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.


  • Rheumatoid Arthritis
    (RA)

    Remsima is the world’s first biosimilar monoclonal antibody (mAb) approved by the European Medicines Agency (EMA) for the treatment of rheumatoid arthritis, and is proven to help improve joint function and inhibit further joint damage in patients with rheumatoid arthritis.

    Learn More
  • Ankylosing Spondylitis (AS)

    Remsima is the world’s first biosimilar monoclonal antibody (mAb) approved by the European Medicines Agency (EMA) for the treatment of Ankylosing Spondylitis, and is proven to reduce signs and symptoms in patients with severe, active AS.

    Learn More
  • Crohn's Disease
    (CD)

    Remsima is the world’s first biosimilar monoclonal antibody (mAb) approved by the European Medicines Agency (EMA) for the treatment of Crohn’s disease, and is proven to help reach and maintain remission in patients with moderately to severely active CD who have not responded well to conventional therapies.

    Learn More
  • Pediatric Crohn's Disease (PCD)

    Remsima is the world’s first biosimilar monoclonal antibody (mAb) approved by the European Medicines Agency (EMA) for the treatment of Crohn’s disease, and is proven to help reach and maintain remission in pediatric patients (age 6-17) with severe, active PCD who have not responded well to conventional therapies.

    Learn More
  • Ulcerative Colitis
    (UC)

    Remsima is the world’s first biosimilar monoclonal antibody (mAb) approved by the European Medicines Agency (EMA) for the treatment of ulcerative colitis, and is proven to help treat the signs and symptoms in adult patients with moderately to severely active UC who have not responded well to other therapies.

    Learn More
  • Pediatric Ulcerative Colitis (PUC)

    Remsima is the world’s first biosimilar monoclonal antibody (mAb) approved by the European Medicines Agency (EMA) for the treatment of ulcerative colitis, and is proven to help treat the signs and symptoms in pediatric patients (age 6-17) with severe, active PUC who have not responded well to other therapies.

    Learn More
  • Plaque Psoriasis
    (PSO)

    Remsima is the world’s first biosimilar monoclonal antibody (mAb) approved by the European Medicines Agency (EMA) for the treatment of plaque psoriasis, and is proven to help treat the signs and symptoms of patients with moderate to severe plaques psoriasis.

    Learn More
  • Psoriatic Arthritis
    (PSA)

    Remsima is the world’s first biosimilar monoclonal antibody (mAb) approved by the European Medicines Agency (EMA) for the treatment of psoriatic arthritis, and is proven to help treat the signs and symptoms and help stop disease progression in patients with progressive PsA.

    Learn More